相关实验视频

Updated: Jul 16, 2025

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

新兴的纳米技术方法来调节瘤血管系统,用于癌症治疗

Chunling Wang¹, Junchao Xu², Yinlong Zhang³

¹CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China; Sino-Danish Center for Education and Research, Sino-Danish College of UCAS, Beijing 100190, China.

Journal of controlled release : official journal of the Controlled Release Society

|September 13, 2023

概括

异常的瘤血管生成为癌症创造了一个敌对的环境. 纳米药物提供精确的血管调节,改善药物输送和降低毒性,用于增强癌症治疗.

科学领域:

在瘤学瘤学.
纳米技术纳米技术
生物医学工程生物医学工程

背景情况:

异常的瘤血管生成是癌症的标志,创造了一个独特的微环境,支持瘤生长和转移.
瘤血管系统在结构和功能上与正常血管系统不同,这给药物输送带来了挑战.
针对血管的药物和纳米药物提供了破坏瘤血液供应和增强治疗结果的策略.

研究的目的:

审查瘤血管的特征,并确定纳米医学设计的关键分子标.
突出纳米技术的进步,以精确调节瘤血管系统.
讨论纳米医学在癌症治疗中的挑战和未来方向.

主要方法:

关于瘤血管生成和纳米医学的当前文献的综述.
对瘤血管结构中的分子点的分析与纳米医药设计相关.
对纳米技术用于癌症血管调节的最新研究的综合.

主要成果:

纳米药物能够精确调节瘤血管结构,并同时提供治疗药物.
纳米药物中的功能性图案可以改善组织积累,透和受控释放.
用纳米药物向瘤血管减少了系统性毒性,提高了治疗疗效.

结论:

纳米药物代表了一种有希望的方法,用于精确调节瘤血管系统.
有针对性的纳米医药设计可以克服传统癌症疗法的局限性.
需要进一步的研究来应对挑战,并优化纳米医学在瘤学中的应用.

关键词:

药物交付是药物交付的过程.纳米医学是一种纳米医学.瘤的饥饿是因为瘤的饥饿.瘤血管系统的结构

更多相关视频

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

相关概念视频

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...